The UK and US have established a major trade agreement that will maintain zero tariffs on British medicine products being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move secures that tariffs on these vital products will stay at zero for a period of 36 months.
This deal follows recent threats to hike tariffs on branded drug products, with figures discussed reaching double the cost.
"This arrangement between the UK reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Impact
Drugs constitute one of the UK's largest export categories to the US, which is easily the largest buyer for leading UK drugmakers.
Export figures indicate that in the year leading up to September, the UK sold drugs valued at billions to the US. This amount made up a significant portion of total UK exports in that span.
"This guarantee protects work, stimulates funding and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several specific commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. Last year, repayments exceeded 20%.
Broader Context
This agreement follows a ongoing dispute between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were exacerbated by arguments that American patients were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a proportion of its resources over the past decade.
